Gilead Sciences Inc. won’t have to fork over additional damages in a patent case over the blockbuster hepatitis C drugs Sovaldi and Harvoni ( Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc. , D. Del., No. 14-846-LPS, 9/22/17 ).
Following a December 2016 jury verdict assessing a record $2.54 billion in damages against Gilead, the drugs’ maker, for infringing a patent held by Merck & Co. subsidiary Idenix Pharmaceuticals LLC, Idenix asked the court to at least double the award because the jury found Gilead’s infringement was willful.
But in a Sept. 22 decision, Judge Leonard P. Stark of the U.S. District Court for the District of Delaware rebuffed Idenix’s request, finding Gilead’s infringement wasn’t egregious enough to warrant increasing the damages. The ruling illustrates patentholders may not always be able to win enhanced damages in infringement cases, even after the Supreme Court made the standards for awarding enhanced damages more flexible in a 2016 decision.
Gilead’s hepatitic C drugs generated $14.8 billion in sales in 2016, down from $19.1 billion in 2015, according to a February company press release. The declines stemmed from lower sales of Sovaldi and Harvoni, which were offset by sales of Epclusa, which the company launched in 2016.
In Halo Electronics, Inc. v. Pulse Electronics, Inc., 136 S. Ct. 1923, 195 L. Ed. 2d 278, 118 U.S.P.Q.2d 1761, 84 U.S.L.W. 4386 (2016), the high court said courts may award enhanced damages in egregious patent infringement cases, where the patent holder can show the infringing party’s behavior is “willful,” “wanton,” “malicious,” “flagrant,” or even “characteristic of a pirate.”
The Halo decision only requires patent holders to show this by a “preponderance of the evidence,” as opposed to the more stringent “clear and convincing evidence” standard.
The parties in this case were battling over U.S. Patent No. 7,608,597, which covers methods and compositions for treating hepatitis C virus.
Idenix, based in Little Rock, Ark., also wasn’t entitled to attorneys’ fees, the court held, because the case wasn’t “exceptional” under the patent statute’s attorneys’ fees provision. Each side’s case had merit, and the parties didn’t act unreasonably during the course of the litigation, the court said.
The ’597 patent was assigned to Idenix and Universita Degli Studi di Cagliari, an Italian university that also was a co-plaintiff in the case.
A spokeswoman for Merck, based in Kenilworth, N.J., said the company is reviewing the decision and considering its options.
“Strong patent protection is essential to innovation,” Merck spokeswoman Claire Gillespie told Bloomberg BNA in a Sept. 25 email. “Given that it guarantees a period of return on investment, patent protection provides the research-based pharmaceutical and biotechnology industries with an incentive to invest in research and development.”
Gilead, based in Foster City, Calif., declined to comment.
Jones Day and Ashby & Geddes represented Idenix and Universita Degli Studi di Cagliari.
Fish & Richardson P.C. represented Gilead.
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
The redacted opinion is available at http://src.bna.com/sOJ.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)